Wen · The Journal of biological chemistry 2011 · Preclinical in vitro and in vivo animal experimental study · n=?

Alternative mitochondrial electron transfer as a novel strategy for neuroprotection.

Cited 250 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical in vitro and animal research with no human data

PubMed 21454572 · doi:10.1074/jbc.M110.208447 · record verified 2026-08-26

What was done

The authors investigated whether methylene blue (MB) could act as an alternative electron carrier in mitochondrial electron transport, comparing it to an N-acetylated MB derivative with a disabled redox center. In cultured neuronal cells, they evaluated oxygen consumption rates, anaerobic glycolysis, and cell survival under toxic insults. In vivo, they tested MB in two animal models: a rotenone-induced Parkinson's disease model (measuring behavioral deficits, striatal dopamine depletion, mitochondrial complex I–III inhibition, free radical production, and nigral dopaminergic neuron loss) and a transient focal cerebral ischemia-reperfusion model.

What was found

The abstract reports directional outcomes without exact numerical values, effect sizes, or p-values. MB accepted electrons from NADH and transferred them to cytochrome c, bypassing complex I/III blockage, whereas the redox-disabled derivative had no effect. In cultured neurons, MB increased oxygen consumption rates, decreased anaerobic glycolysis, and provided protection at nanomolar concentrations. In the Parkinson's disease model, MB almost completely rescued striatal dopamine depletion, attenuated complex I–III inhibition, reduced free radical overproduction, and preserved nigral dopaminergic neurons and behavioral performance. MB also significantly reduced reperfusion injury in the cerebral ischemia model.

Why it matters

By rerouting electron flow past blocked respiratory complexes, alternative electron carriers offer a potential metabolic strategy for neuroprotection distinct from traditional radical scavenging.

Limits

All data are from cell culture and animal models, with no clinical human testing. The abstract provides no specific sample sizes, animal species, dosing regimens, or quantitative outcome metrics.

Cited by